miR‑106b‑5p promotes cell proliferation and cell cycle progression by directly targeting CDKN1A in osteosarcoma

He,Chuan; Chen,Hongwei; Liu,Yan; Li,Xiaolin; Zhang,Chaoju; Qin,Qunyan; Pang,Qixiong

doi:10.3892/etm.2020.8574

miR‑106b‑5p promotes cell proliferation and cell cycle progression by directly targeting CDKN1A in osteosarcoma

Authors:
- Chuan He
- Hongwei Chen
- Yan Liu
- Xiaolin Li
- Chaoju Zhang
- Qunyan Qin
- Qixiong Pang
View Affiliations

Affiliations: Department of Orthopedics, Jingzhou Traditional Chinese Medicine Hospital, Jingzhou, Hubei 434000, P.R. China
Published online on: March 6, 2020 https://doi.org/10.3892/etm.2020.8574
Pages: 3203-3210
Copyright: © He et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNA (miR)‑106b‑5p has been reported to act as both an oncogene and tumor suppressor in several tumors. The aim of the present study was to investigate the biological function of miR‑106b‑5p in osteosarcoma (OS). miR‑106b‑5p expression was observed to be significantly increased in OS tissues and cell lines. MTT assay and flow cytometry analysis determined that miR‑106b‑5p inhibitor transfection suppressed OS cell proliferation and induced cell cycle G0/G1 phase arrest. Furthermore, bioinformatics analysis and a luciferase reporter assay demonstrated that cyclin‑dependent kinase inhibitor 1A (CDKN1A) was a potential target of miR‑106b‑5p. p21 protein expression was found to be significantly increased by miR‑106b‑5p downregulation in OS cells. Further analysis demonstrated that CDKN1A was downregulated in OS tissues and was negatively correlated with miR‑106b‑5p expression. Furthermore, upregulation of CDKN1A expression mimicked, whilst CDKN1A knockdown reversed the suppressive effects of miR‑106b‑5p inhibitor on OS cell proliferation and cell cycle progression. In summary, the present data suggested that miR‑106b‑5p promotes cell proliferation and cell cycle progression by directly targeting CDKN1A in OS.

View Figures

View References

1	Verrecchia F and Rédini F: Transforming growth factor-β signaling plays a pivotal role in the interplay between osteosarcoma cells and their microenvironment. Front Oncol. 8(133)2018.PubMed/NCBI View Article : Google Scholar
2	Luetke A, Meyers PA, Lewis I and Juergens H: Osteosarcoma treatment-Where do we stand? A state of the art review. Cancer Treat Rev. 40:523–532. 2014.PubMed/NCBI View Article : Google Scholar
3	Piletic K and Kunej T: MicroRNA epigenetic signatures in human disease. Arch Toxicol. 90:2405–2419. 2016.PubMed/NCBI View Article : Google Scholar
4	Apprey V, Wang S, Tang W, Kittles RA, Southerland WM, Ittmann M and Kwabi-Addo B: Association of Genetic ancestry with DNA methylation changes in prostate cancer disparity. Anticancer Res. 39:5861–5866. 2019.PubMed/NCBI View Article : Google Scholar
5	Lin S and Gregory RI: MicroRNA biogenesis pathways in cancer. Nat Rev Cancer. 15:321–333. 2015.PubMed/NCBI View Article : Google Scholar
6	Wang J, Liu S, Shi J, Li J, Wang S, Liu H, Zhao S, Duan K, Pan X and Yi Z: The Role of miRNA in the diagnosis, prognosis, and treatment of osteosarcoma. Cancer Biother Radiopharm. 34:605–613. 2019.PubMed/NCBI View Article : Google Scholar
7	Ma X, Li D, Gao Y and Liu C: miR-451a inhibits the growth and invasion of osteosarcoma via targeting TRIM66. Technol Cancer Res Treat. 18(1533033819870209)2019.PubMed/NCBI View Article : Google Scholar
8	Marx V: Meet some code-breakers of noncoding RNAs. Nat Methods. 15:103–106. 2018.PubMed/NCBI View Article : Google Scholar
9	Yamamoto N, Nishikawa R, Chiyomaru T, Goto Y, Fukumoto I, Usui H, Mitsuhashi A, Enokida H, Nakagawa M, Shozu M and Seki N: The tumor-suppressive microRNA-1/133a cluster targets PDE7A and inhibits cancer cell migration and invasion in endometrial cancer. Int J Oncol. 47:325–334. 2015.PubMed/NCBI View Article : Google Scholar
10	Wong N and Wang X: miRDB: An online resource for microRNA target prediction and functional annotations. Nucleic Acids Res. 43:D146–D152. 2015.PubMed/NCBI View Article : Google Scholar
11	Xiang W, He J, Huang C, Chen L, Tao D, Wu X, Wang M, Luo G, Xiao X, Zeng F and Jiang G: miR-106b-5p targets tumor suppressor gene SETD2 to inactive its function in clear cell renal cell carcinoma. Oncotarget. 6:4066–4079. 2015.PubMed/NCBI View Article : Google Scholar
12	Shi DM, Bian XY, Qin CD and Wu WZ: miR-106b-5p promotes stem cell-like properties of hepatocellular carcinoma cells by targeting PTEN via PI3K/Akt pathway. Onco Targets Ther. 11:571–585. 2018.PubMed/NCBI View Article : Google Scholar
13	Liu F, Gong J, Huang W, Wang Z, Wang M, Yang J, Wu C, Wu Z and Han B: MicroRNA-106b-5p boosts glioma tumorigensis by targeting multiple tumor suppressor genes. Oncogene. 33:4813–4822. 2014.PubMed/NCBI View Article : Google Scholar
14	Chen X, Chen P, Chen SS, Ma T, Shi G, Zhou Y, Li J and Sheng L: miR106b5p promotes cell cycle progression of malignant melanoma by targeting PTEN. Oncol Rep. 39:331–337. 2018.PubMed/NCBI View Article : Google Scholar
15	Wei K, Pan C, Yao G, Liu B, Ma T, Xia Y, Jiang W, Chen L and Chen Y: MiR-106b-5p promotes proliferation and inhibits apoptosis by regulating BTG3 in Non-small cell lung cancer. Cell Physiol Biochem. 44:1545–1558. 2017.PubMed/NCBI View Article : Google Scholar
16	Malumbres M: Cyclin-dependent kinases. Genome Biol. 15(122)2014.PubMed/NCBI View Article : Google Scholar
17	Kreis NN, Louwen F and Yuan J: Less understood issues: p21(Cip1) in mitosis and its therapeutic potential. Oncogene. 34:1758–1767. 2015.PubMed/NCBI View Article : Google Scholar
18	Abbas T and Dutta A: p21 in cancer: Intricate networks and multiple activities. Nat Rev Cancer. 9:400–414. 2009.PubMed/NCBI View Article : Google Scholar
19	Fitzgerald AL, Osman AA, Xie TX, Patel A, Skinner H, Sandulache V and Myers JN: Reactive oxygen species and p21Waf1/Cip1 are both essential for p53-mediated senescence of head and neck cancer cells. Cell Death Dis. 6(e1678)2015.PubMed/NCBI View Article : Google Scholar
20	Wu Z, Liu K, Wang Y, Xu Z, Meng J and Gu S: Upregulation of microRNA-96 and its oncogenic functions by targeting CDKN1A in bladder cancer. Cancer Cell Int. 15(107)2015.PubMed/NCBI View Article : Google Scholar
21	Ohta K, Hoshino H, Wang J, Ono S, Iida Y, Hata K, Huang SK, Colquhoun S and Hoon DS: MicroRNA-93 activates c-Met/PI3K/Akt pathway activity in hepatocellular carcinoma by directly inhibiting PTEN and CDKN1A. Oncotarget. 6:3211–3224. 2015.PubMed/NCBI View Article : Google Scholar
22	Brock M, Haider TJ, Vogel J, Gassmann M, Speich R, Trenkmann M, Ulrich S, Kohler M and Huber LC: The hypoxia-induced microRNA-130a controls pulmonary smooth muscle cell proliferation by directly targeting CDKN1A. Int J Biochem Cell Biol. 61:129–137. 2015.PubMed/NCBI View Article : Google Scholar
23	Fornari F, Milazzo M, Chieco P, Negrini M, Marasco E, Capranico G, Mantovani V, Marinello J, Sabbioni S, Callegari E, et al: In hepatocellular carcinoma miR-519d is up-regulated by p53 and DNA hypomethylation and targets CDKN1A/p21, PTEN, AKT3 and TIMP2. J Pathol. 227:275–285. 2012.PubMed/NCBI View Article : Google Scholar
24	Shao M, Geng Y, Lu P, Xi Y, Wei S, Wang L, Fan Q and Ma W: miR-4295 promotes cell proliferation and invasion in anaplastic thyroid carcinoma via CDKN1A. Biochem Biophys Res Commun. 464:1309–1313. 2015.PubMed/NCBI View Article : Google Scholar
25	Zhao X, Yang Y, Xu J, Luo Y, Xin Y and Wang Y: Downregulation of microRNA-95-3p suppresses cell growth of osteosarcoma via CDKN1A/p21 expression. Oncol Rep. 39:289–297. 2018.PubMed/NCBI View Article : Google Scholar
26	Livak K and Schmittgen T: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2000.PubMed/NCBI View Article : Google Scholar
27	Ni S, Weng W, Xu M, Wang Q, Tan C, Sun H, Wang L, Huang D, Du X and Sheng W: miR-106b-5p inhibits the invasion and metastasis of colorectal cancer by targeting CTSA. Onco Targets Ther. 11:3835–3845. 2018.PubMed/NCBI View Article : Google Scholar
28	Lee E, Collazo-Lorduy A, Castillo-Martin M, Gong Y, Wang L, Oh WK, Galsky MD, Cordon-Cardo C and Zhu J: Identification of microR-106b as a prognostic biomarker of p53-like bladder cancers by ActMiR. Oncogene. 37:5858–5872. 2018.PubMed/NCBI View Article : Google Scholar
29	Evan GI and Vousden KH: Proliferation, cell cycle and apoptosis in cancer. Nature. 411:342–348. 2001.PubMed/NCBI View Article : Google Scholar
30	Wood DJ and Endicott JA: Structural insights into the functional diversity of the CDK-cyclin family. Open Biol. 8(180112)2018.PubMed/NCBI View Article : Google Scholar
31	Sánchez-Martínez C, Gelbert LM, Lallena MJ and de Dios A: Cyclin dependent kinase (CDK) inhibitors as anticancer drugs. Bioorg Med Chem Lett. 25:3420–3435. 2015.PubMed/NCBI View Article : Google Scholar
32	Abbadie C, Pluquet O and Pourtier A: Epithelial cell senescence: An adaptive response to pre-carcinogenic stresses? Cell Mol Life Sci. 74:4471–4509. 2017.PubMed/NCBI View Article : Google Scholar
33	Dong X, Hu X, Chen J, Hu D and Chen LF: BRD4 regulates cellular senescence in gastric cancer cells via E2F/miR-106b/p21 axis. Cell Death Dis. 9(203)2018.PubMed/NCBI View Article : Google Scholar
34	Sun K, Jia Z, Duan R, Yan Z, Jin Z, Yan L, Li Q and Yang J: Long non-coding RNA XIST regulates miR-106b-5p/P21 axis to suppress tumor progression in renal cell carcinoma. Biochem Biophys Res Commun. 510:416–420. 2019.PubMed/NCBI View Article : Google Scholar